2 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow Omacetaxine: new trials by email Literature Review of Omacetaxine trials Research Report on Omacetaxine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS Omacetaxine, Azacitidine - High Grade Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 29 | 2018-09-17 | 2026-11-06 |
| A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) Omacetaxine, Azacitidine, G-CSF - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Withdrawn | University of Florida | 2016-08-01 | 2017-05-03 | |
| Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure Omacetaxine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2015-05-18 | 2021-06-09 |
| Omacetaxine for Consolidation and Maintenance Omacetaxine - Acute Myelogenous Leukemia (AML) | Phase 2 | Terminated | Emory University | 7 | 2013-05-01 | 2019-09-24 |
| Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Omacetaxine, Cytarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 36 | 2011-07-01 | 2018-05-30 |
Leukemia (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2)
M.D. Anderson Cancer Center (2) · Emory University (1) · University of Colorado, Denver (1) · University of Florida (1)
United States (5)
Daniel Pollyea, MD (1) · Elias Jabbour, MD (1) · Hagop Kantarjian, MD (1) · Martha L. Arellano, MD (1) · Maxim N. Norkin, MD, PhD (1)